Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders-Reference-Cited by-同舟云学术

Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders

Published:2021 Issue:3-4 Volume:43 Page:247-252
ISSN:0378-5866
Container-title:Developmental Neuroscience
language:en
Short-container-title:Dev Neurosci

Author:

Hill Sophie F.,Meisler Miriam H.

Abstract

Antisense oligonucleotides (ASOs) are short oligonucleotides that can modify gene expression and mRNA splicing in the nervous system. The FDA has approved ASOs for treatment of ten genetic disorders, with many applications currently in the pipeline. We describe the molecular mechanisms of ASO treatment for four neurodevelopmental and neuromuscular disorders. The ASO nusinersen is a general treatment for mutations of SMN1 in spinal muscular atrophy that corrects the splicing defect in the SMN2 gene. Milasen is a patient-specific ASO that rescues splicing of CNL7 in Batten’s disease. STK-001 is an ASO that increases expression of the sodium channel gene SCN1A by exclusion of a poison exon. An ASO that reduces the abundance of the SCN8A mRNA is therapeutic in mouse models of developmental and epileptic encephalopathy. These examples demonstrate the variety of mechanisms and range of applications of ASOs for treatment of neurodevelopmental disorders.

Publisher

S. Karger AG

Subject

Developmental Neuroscience,Neurology

Reference24 articles.

1. Corey DR. Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nat Neurosci. Apr 2017;20(4):497–9.

2. Kim J, Hu C, Moufawad El Achkar C, Black LE, Douville J, Larson A, et al. Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med. 2019;381(17):1644–52.

3. Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant Huntingtin. Mol Ther. Dec 2011;19(12):2178–85.

4. Monia BP, Lesnik EA, Gonzalez C, Lima WF, McGee D, Guinosso CJ, et al. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem. 1993;268(19):14514–22.

5. McKay RA, Miraglia LJ, Cummins LL, Owens SR, Sasmor H, Dean NM. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem. Jan 1999;274(3):1715–22.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling;Journal of Neuromuscular Diseases;2024-01-05

2. The landscape of nanoparticle-based siRNA delivery and therapeutic development;Molecular Therapy;2024-01

3. A fluorescent splice-switching mouse model enables high-throughput, sensitive quantification of antisense oligonucleotide delivery and activity;Cell Reports Methods;2024-01

4. A bibliometric analysis of acupuncture for neurodevelopmental disorders: A Call for increased output and future research priorities;Heliyon;2023-12

5. Using the structural diversity of RNA: protein interfaces to selectively target RNA with small molecules in cells: methods and perspectives;Frontiers in Molecular Biosciences;2023-11-16